A novel anti-atherogenic role for COX-2--potential mechanism for the cardiovascular side effects of COX-2 inhibitors
- PMID: 17643885
- PMCID: PMC2701232
- DOI: 10.1016/j.prostaglandins.2007.03.004
A novel anti-atherogenic role for COX-2--potential mechanism for the cardiovascular side effects of COX-2 inhibitors
Abstract
Atherosclerosis, the underlying cause of cardiovascular disease, is characterized by lipid accumulation, lipoprotein oxidation, and inflammation. Products of the cyclooxygenase (COX) pathway participate in acute and chronic inflammation. The inducible form of COX, COX-2, generates lipid mediators of inflammation that are pro-inflammatory and COX-2-selective inhibitors are potent anti-inflammatory agents. However, clinical data suggest an increased risk of cardiovascular side effects in patients using COX-2-selective inhibitors. In this paper, we sought to determine the effect of COX-2 deficiency on atherosclerosis-related lipoprotein metabolism in mice. We demonstrate that COX-2 deficiency resulted in (i) accumulation of lipids in circulation and liver, (ii) pro-inflammatory properties of HDL as measured by HDL's increased reactive oxygen species (ROS) content, decreased paraoxonase 1 (PON1) activity, decreased serum apoA-1, reduced ability to efflux cholesterol and to prevent LDL oxidizability, and (iii) increased TXB(2) in circulation. Moreover, when placed on an atherogenic diet, COX-2 deficiency resulted in (i) increased lipid deposition in the aorta, (ii) a further dramatic imbalance in circulating eicosanoids, i.e. decreased serum PGI(2) coupled with increased PGE(2) and TXB(2), and (iii) a marked elevation of pro-inflammatory cytokines, TNF and IL-6. Our results suggest, for the first time, that COX-2 deficiency contributes to the pro-atherogenic properties of HDL in mice.
Figures





Similar articles
-
Effect of cyclooxygenase inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk.Arthritis Res Ther. 2007;9(1):R4. doi: 10.1186/ar2109. Arthritis Res Ther. 2007. PMID: 17244362 Free PMC article.
-
Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.Circ Res. 2004 Oct 15;95(8):789-97. doi: 10.1161/01.RES.0000146031.94850.5f. Epub 2004 Sep 23. Circ Res. 2004. PMID: 15388641
-
The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis.Atherosclerosis. 2016 Jun;249:200-8. doi: 10.1016/j.atherosclerosis.2016.03.003. Epub 2016 Mar 4. Atherosclerosis. 2016. PMID: 27108950
-
Systemic inflammation, intestine, and paraoxonase-1.Adv Exp Med Biol. 2014;824:83-8. doi: 10.1007/978-3-319-07320-0_8. Adv Exp Med Biol. 2014. PMID: 25038995 Review.
-
Anti-inflammatory properties of paraoxonase-1 in atherosclerosis.Adv Exp Med Biol. 2010;660:143-51. doi: 10.1007/978-1-60761-350-3_13. Adv Exp Med Biol. 2010. PMID: 20221877 Review.
Cited by
-
Global deletion of COX-2 attenuates hepatic inflammation but impairs metabolic homeostasis in diet-induced obesity.J Lipid Res. 2025 Jun;66(6):100823. doi: 10.1016/j.jlr.2025.100823. Epub 2025 May 8. J Lipid Res. 2025. PMID: 40345662 Free PMC article.
-
Microsomal Prostaglandin E Synthase-1 Expression by Aortic Smooth Muscle Cells Attenuates the Differentiated Phenotype.J Cardiovasc Pharmacol. 2016 Aug;68(2):127-42. doi: 10.1097/FJC.0000000000000395. J Cardiovasc Pharmacol. 2016. PMID: 27159620 Free PMC article.
-
Mechanistic definition of the cardiovascular mPGES-1/COX-2/ADMA axis.Cardiovasc Res. 2020 Oct 1;116(12):1972-1980. doi: 10.1093/cvr/cvz290. Cardiovasc Res. 2020. PMID: 31688905 Free PMC article.
-
Eicosanoids and cancer.Nat Rev Cancer. 2010 Mar;10(3):181-93. doi: 10.1038/nrc2809. Epub 2010 Feb 19. Nat Rev Cancer. 2010. PMID: 20168319 Free PMC article. Review.
-
Absence of myeloid COX-2 attenuates acute inflammation but does not influence development of atherosclerosis in apolipoprotein E null mice.Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):260-8. doi: 10.1161/ATVBAHA.109.198762. Epub 2009 Nov 19. Arterioscler Thromb Vasc Biol. 2010. PMID: 19926832 Free PMC article.
References
-
- Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. Jama. 1986;256:2835–8. - PubMed
-
- Navab M, Ananthramaiah GM, Reddy ST, et al. The double jeopardy of HDL. Ann Med. 2005;37:173–8. - PubMed
-
- Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM. Mechanisms of disease: proatherogenic HDL--an evolving field. Nat Clin Pract Endocrinol Metab. 2006;2:504–11. - PubMed
-
- Ansell BJ, Navab M, Hama S, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108:2751–6. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous